Menu
Search
|

Menu

Close
X

BioDelivery Sciences International Inc BDSI.OQ (NASDAQ Stock Exchange Capital Market)

2.78 USD
-0.08 (-2.63%)
As of 8:40 PM IST
chart
Previous Close 2.85
Open 2.85
Volume 3,685
3m Avg Volume 52,910
Today’s High 2.85
Today’s Low 2.78
52 Week High 3.60
52 Week Low 1.70
Shares Outstanding (mil) 55.48
Market Capitalization (mil) 166.43
Forward P/E 262.01
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
11
FY17
62
FY16
16
FY15
48
EPS (USD)
FY18
-0.184
FY17
0.098
FY16
-1.258
FY15
-0.720
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
262.01
32.76
Price to Sales (TTM)
vs sector
3.64
5.73
Price to Book (MRQ)
vs sector
6.34
5.45
Price to Cash Flow (TTM)
vs sector
32.01
23.29
Total Debt to Equity (MRQ)
vs sector
134.19
16.72
LT Debt to Equity (MRQ)
vs sector
134.19
12.39
Return on Investment (TTM)
vs sector
2.67
14.61
Return on Equity (TTM)
vs sector
9.28
16.34

EXECUTIVE LEADERSHIP

Frank O'Donnell
Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
Scott Plesha
President, Since 2018
Salary: --
Bonus: --
Herm Cukier
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Mark Sirgo
Vice Chairman of the Board, Since 2017
Salary: $550,000.00
Bonus: $143,700.00
Ernest De Paolantonio
Chief Financial Officer, Treasurer, Secretary, Since 2015
Salary: $350,000.00
Bonus: $52,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4131 Parklake Ave Ste 225
RALEIGH   NC   27612-2390

Phone: +1919.5829050

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

SPONSORED STORIES